Alignment Healthcare (ALHC)
(Delayed Data from NSDQ)
$11.45 USD
+0.14 (1.24%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $11.44 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.45 USD
+0.14 (1.24%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $11.44 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Zacks News
Strength Seen in Alignment Healthcare (ALHC): Can Its 6.5% Jump Turn into More Strength?
by Zacks Equity Research
Alignment Healthcare (ALHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Alignment Healthcare (ALHC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alignment Healthcare (ALHC) delivered earnings and revenue surprises of -3.33% and 6.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of -12.50% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Alignment Healthcare (ALHC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 12% and 8%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia (ACHC) JV Breaks Ground for New Behavioral Health Unit
by Zacks Equity Research
Acadia Healthcare (ACHC) and Henry Ford Health expect the new hospital to start with 184 inpatient beds and later expand to 192 beds.
UnitedHealth (UNH) Wins New Medicaid Contract in Nebraska
by Zacks Equity Research
UnitedHealth's (UNH) UnitedHealthcare boasts a network of 100 hospitals and more than 14,000 physicians and caregivers in Nebraska.
Encompass Health (EHC) Opens New 50-Bed Hospital in Naples
by Zacks Equity Research
With the new facility in Naples, Encompass Health (EHC) now has 153 inpatient rehabilitation units in total.
HCA Healthcare (HCA) Invests in VitalConnect's Remote Monitoring
by Zacks Equity Research
HCA Healthcare's (HCA) investment is likely to advance technology in the medical space, helping patients as well as professionals.
Is Aerie Pharmaceuticals (AERI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aerie Pharmaceuticals (AERI) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
Is Alignment Healthcare (ALHC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alignment Healthcare (ALHC) and Hanger (HNGR) have performed compared to their sector so far this year.
Wall Street Analysts See a 33% Upside in Alignment Healthcare (ALHC): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 32.9% upside potential for Alignment Healthcare (ALHC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has Alignment Healthcare (ALHC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alignment Healthcare (ALHC) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
Alignment Healthcare (ALHC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 76.92% and 8.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Alignment Healthcare (ALHC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 4.17% and 3.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Alignment Healthcare (ALHC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Alignment Healthcare (ALHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.